Patrick Amstutz
Net worth: 3 M $ as of 2026-06-29
Net worth: 3 M $ as of 2026-06-29
Patrick Amstutz is the founder of Molecular Partners AG, founded in 2004, holding the title of Chief Executive Officer & Director since 2017.
Dr. Amstutz currently holds the positions of Chief Executive Officer & Director at Molecular Partners, Inc. and President at the Swiss Biotech Association since 2022.
Dr. Amstutz completed a doctorate at the University of Zurich and a graduate degree at the Swiss Federal Institute of Technology.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2025-12-30 | 759,913 ( 1.88% ) | 3 M $ | 2026-06-29 |
| Companies | Position | Start |
|---|---|---|
| MOLECULAR PARTNERS AG | Founder | 2004-11-21 |
Swiss Biotech Association
Swiss Biotech Association Miscellaneous Commercial ServicesCommercial Services Operates as an industry association | President | 2022-05-02 |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company | Chief Executive Officer | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
University of Zurich
University of Zurich Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Swiss Federal Institute of Technology
Swiss Federal Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Molecular Partners AG
Molecular Partners AG BiotechnologyHealth Technology Engages in discovery, development and commercialization of biopharmaceutical products | Health Technology |
Swiss Biotech Association
Swiss Biotech Association Miscellaneous Commercial ServicesCommercial Services Operates as an industry association | Commercial Services |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Select your edition
All financial news and data tailored to specific country editions